Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease
Open Access
- 20 November 2024
- journal article
- research article
- Published by Elsevier in Journal of Genetic Engineering and Biotechnology
- Vol. 22 (4) , 100438
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese AdultsJACC, 2024
- Adropin: A crucial regulator of cardiovascular health and metabolic balanceMetabolism Open, 2024
- Circulating levels of adropin and overweight/obesity: a systematic review and meta-analysis of observational studiesHormones, 2021
- Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With DiabetesKidney International Reports, 2020
- Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus ConferenceKidney International, 2020
- Type 2 Diabetes and Chronic Conditions Disparities in Medicare Beneficiaries in the State of MichiganThe American Journal of the Medical Sciences, 2020
- Global case studies for chronic kidney disease/end-stage kidney disease careKidney International Supplements, 2020
- Cardiovascular Disease in Chronic Kidney Disease2019
- Lessons from 30 years’ data of Korean end-stage renal disease registry, 1985–2015Kidney Research and Clinical Practice, 2015
- Three new players in energy regulation: Preptin, adropin and irisinPeptides, 2014